Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services, signed a letter of intent to develop and license formulation packages, specifically for implementation by their customers. The companies intend to deliver “ready-to-implement” patient-friendly drug formulations that provide convenience, compliance, and efficacy for such therapeutic indications as intense pain, opioid addiction, and central nervous system conditions (epilepsy, migraine, etc.).
Noramco has previously pledged to help its customers around the world accelerate pharmaceutical development with technical solutions packages. “Partnering with SPI Pharma enables Noramco to bring together API and functional excipient science to deliver innovative, patient-friendly solutions to formulators of finished dosage forms,” said Bill Grubb, VP Global Strategy and Innovation.
Grubb went on to say that going to generic and branded pharmaceutical customers with formulation packages allows Noramco and SPI Pharma to directly support speed-to-market, a reduction in trial-and-error, product differentiation, life-cycle management, and technical/regulatory support.
“Our customers will have the ability to work in a fee-for-service or royalty arrangement, and implement the technology at the facility they choose,” added Grubb. Following a definitive agreement, which is expected in the next 30 days, testing of a select group of cannabinoid and addiction treatment APIs in unique dosage forms will commence to establish proof of concept (POC).
Noramco, spi pharma ink collaboration to develop formulation solution packages
2.png)
